ARID1A and metastatic prostate carcinoma: We predicted monoallelic ARID1A LOF (PR-AUC-E = 0.208; AUROC = 0.72) by depletion of SBS signature 8 mutations in metastatic prostate cancer (Figure 6—figure supplement 1a).